CJC-1295 and CJC-1295 DAC are both modified analogs of growth hormone-releasing hormone (GHRH), but they differ significantly in their pharmacokinetic profiles due to the Drug Affinity Complex (DAC) modification. Understanding these differences is essential for selecting the appropriate analog in GH axis research.
Structural Comparison
CJC-1295 (also known as modified GRF 1-29 or “CJC-1295 without DAC”) is a 29-amino-acid peptide derived from the first 29 residues of human GHRH with four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) that improve metabolic stability. These substitutions protect against enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV) and other proteases, extending the half-life from approximately 7 minutes (native GHRH) to roughly 30 minutes.
CJC-1295 DAC adds a lysine-linked maleimidopropionic acid moiety (the Drug Affinity Complex) that binds covalently and irreversibly to serum albumin after administration. This albumin conjugation dramatically extends the circulating half-life to approximately 6–8 days, creating a fundamentally different pharmacokinetic profile. The DAC technology was originally developed by ConjuChem Biotechnologies to create long-acting peptide therapeutics.
Pharmacokinetic Differences
CJC-1295 without DAC produces acute GH pulses following each administration, with peak GH levels occurring within 15–30 minutes and returning to baseline within 2–3 hours. This pulsatile pattern closely mimics the natural episodic GH secretion controlled by hypothalamic GHRH release. Multiple daily administrations are typically used in research protocols to maintain elevated GH signaling.
CJC-1295 DAC, due to its extended half-life, produces sustained elevation of baseline GH levels rather than discrete pulses. A single administration raises GH and IGF-1 levels for days to over a week. Published research has shown that CJC-1295 DAC increased mean GH concentrations 2- to 10-fold and IGF-1 levels by 1.5- to 3-fold for 6 or more days following a single dose in studied models. This sustained elevation pattern differs from natural physiology, which is characterized by pulsatile release.
Research Considerations
The choice between the two analogs depends on the research question. CJC-1295 without DAC is preferred when studying acute GH responses, GH pulsatility, or when combined with GHRPs (where the synergistic pulse is the desired readout). CJC-1295 DAC is more suitable for studies requiring sustained GH/IGF-1 elevation, compliance-critical protocols with less frequent dosing, or investigations into the effects of chronic GH axis stimulation. Researchers should consider that the sustained profile of CJC-1295 DAC may desensitize the GH axis over time, a factor that should be controlled for in study design.
Frequently Asked Questions
Can CJC-1295 (no DAC) and a GHRP be combined in research?
Yes, this is a common research protocol. Combining a GHRH analog like CJC-1295 with a GHRP such as ipamorelin produces synergistic GH release because the two peptides act through complementary receptor systems (GHRHR and GHSR). This combination has been shown to produce GH pulses significantly greater than either peptide alone in preclinical models.
Does CJC-1295 DAC cause continuous GH release?
CJC-1295 DAC elevates baseline GH levels and amplifies natural GH pulses rather than causing truly continuous secretion. The pituitary still responds to somatostatin inhibition, so some pulsatility is preserved, but the overall pattern is distinctly different from the sharp, discrete pulses seen with the non-DAC version. The blunted pulsatility may have different downstream effects on GH-responsive tissues.